Literature DB >> 31336074

Fetal cardiac remodeling and dysfunction is associated with both preeclampsia and fetal growth restriction.

Lina Youssef1, Jezid Miranda1, Cristina Paules1, Laura Garcia-Otero1, Kilian Vellvé1, Grigorios Kalapotharakos2, Alvaro Sepulveda-Martinez3, Francesca Crovetto1, Olga Gomez1, Eduard Gratacós4, Fatima Crispi1.   

Abstract

BACKGROUND: Preeclampsia and fetal growth restriction share some pathophysiologic features and are both associated with placental insufficiency. Fetal cardiac remodeling has been described extensively in fetal growth restriction, whereas little is known about preeclampsia with a normally grown fetus.
OBJECTIVE: To describe fetal cardiac structure and function in pregnancies complicated by preeclampsia and/or fetal growth restriction as compared with uncomplicated pregnancies. STUDY
DESIGN: This was a prospective, observational study including pregnancies complicated by normotensive fetal growth restriction (n=36), preeclampsia with a normally grown fetus (n=35), preeclampsia with fetal growth restriction (preeclampsia with a normally grown fetus-fetal growth restriction, n=42), and 111 uncomplicated pregnancies matched by gestational age at ultrasound. Fetal echocardiography was performed at diagnosis for cases and recruitment for uncomplicated pregnancies. Cord blood concentrations of B-type natriuretic peptide and troponin I were measured at delivery. Univariate and multiple regression analysis were conducted.
RESULTS: Pregnancies complicated by preeclampsia and/or fetal growth restriction showed similar patterns of fetal cardiac remodeling with larger hearts (cardiothoracic ratio, median [interquartile range]: uncomplicated pregnancies 0.27 [0.23-0.29], fetal growth restriction 0.31 [0.26-0.34], preeclampsia with a normally grown fetus 0.31 [0.29-0.33), and preeclampsia with fetal growth restriction 0.28 [0.26-0.33]; P<.001) and more spherical right ventricles (right ventricular sphericity index: uncomplicated pregnancies 1.42 [1.25-1.72], fetal growth restriction 1.29 [1.22-1.72], preeclampsia with a normally grown fetus 1.30 [1.33-1.51], and preeclampsia with fetal growth restriction 1.35 [1.27-1.46]; P=.04) and hypertrophic ventricles (relative wall thickness: uncomplicated pregnancies 0.55 [0.48-0.61], fetal growth restriction 0.67 [0.58-0.8], preeclampsia with a normally grown fetus 0.68 [0.61-0.76], and preeclampsia with fetal growth restriction 0.66 [0.58-0.77]; P<.001). Signs of myocardial dysfunction also were observed, with increased myocardial performance index (uncomplicated pregnancies 0.78 z scores [0.32-1.41], fetal growth restriction 1.48 [0.97-2.08], preeclampsia with a normally grown fetus 1.15 [0.75-2.17], and preeclampsia with fetal growth restriction 0.45 [0.54-1.94]; P<.001) and greater cord blood B-type natriuretic peptide (uncomplicated pregnancies 14.2 [8.4-30.9] pg/mL, fetal growth restriction 20.8 [13.1-33.5] pg/mL, preeclampsia with a normally grown fetus 31.8 [16.4-45.8] pg/mL and preeclampsia with fetal growth restriction 37.9 [15.7-105.4] pg/mL; P<.001) and troponin I as compared with uncomplicated pregnancies.
CONCLUSION: Fetuses of preeclamptic mothers, independently of their growth patterns, presented cardiovascular remodeling and dysfunction in a similar fashion to what has been previously described for fetal growth restriction. Future research is warranted to better elucidate the mechanism(s) underlying fetal cardiac adaptation in these conditions.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B-type natriuretic peptide; cardiovascular remodeling; fetal echocardiography; fetal programming; intrauterine growth restriction; pregnancy hypertension; troponin I

Year:  2019        PMID: 31336074     DOI: 10.1016/j.ajog.2019.07.025

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Assessment of myocardial injury in neonates born to pregnant women with pregnancy complicated by severe preeclampsia by myocardial work indices: a prospective study.

Authors:  Hui-Yun Chen; Tao Pan; Hong Li; Qiu-Qin Xu; Fang-Can Sun; Bing Han; Xin-Xian Gu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-02-15

2.  Overexpression of microRNAs miR-25-3p, miR-185-5p and miR-132-3p in Late Onset Fetal Growth Restriction, Validation of Results and Study of the Biochemical Pathways Involved.

Authors:  Gabriela Loscalzo; Julia Scheel; José Santiago Ibañez-Cabellos; Eva García-Lopez; Shailendra Gupta; José Luis García-Gimenez; Salvador Mena-Mollá; Alfredo Perales-Marín; José Morales-Roselló
Journal:  Int J Mol Sci       Date:  2021-12-28       Impact factor: 5.923

3.  Cardiac dysfunction and remodeling regulated by anti-angiogenic environment in patients with preeclampsia: the ANGIOCOR prospective cohort study protocol.

Authors:  Johana Ullmo; Monica Cruz-Lemini; Olga Sánchez-García; Lidia Bos-Real; Patricia Fernandez De La Llama; Francesca Calero; Carla Domínguez-Gallardo; Carmen Garrido-Gimenez; Cristina Trilla; Francesc Carreras-Costa; Alessandro Sionis; Josefina Mora; Álvaro García-Osuna; Jordi Ordoñez-Llanos; Elisa Llurba
Journal:  BMC Pregnancy Childbirth       Date:  2021-12-08       Impact factor: 3.007

Review 4.  Pregnancy Complications Lead to Subclinical Maternal Heart Dysfunction-The Importance and Benefits of Follow-Up Using Speckle Tracking Echocardiography.

Authors:  Mihaela Roxana Popescu; Alexandra Bouariu; Anca Marina Ciobanu; Nicolae Gică; Anca Maria Panaitescu
Journal:  Medicina (Kaunas)       Date:  2022-02-15       Impact factor: 2.430

5.  Childhood cardiovascular morphology and function following abnormal fetal growth.

Authors:  Rasmus F W Olander; Linda Litwin; Johnny K M Sundholm; Taisto Sarkola
Journal:  Heart Vessels       Date:  2022-04-15       Impact factor: 1.814

Review 6.  The Global Pregnancy Collaboration (CoLab) symposium on short- and long-term outcomes in offspring whose mothers had preeclampsia: A scoping review of clinical evidence.

Authors:  Steven J Korzeniewski; Elizabeth Sutton; Carlos Escudero; James M Roberts
Journal:  Front Med (Lausanne)       Date:  2022-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.